Oyster Point Pharma Inc

Oyster Point Pharma — Corporate Update (January 2020)

34 slides from Oyster Point Pharma's corporate update, Jan 14, 2020

  1. Slide 1: January 2020 Corporate Update

    Exhibit 99.1 January 2020 Corporate Update NASDAQ: OYSTExhibit 99.1 January 2020 Corporate Update NASDAQ: OYST

  2. Slide 2: Disclaimers and Forward Looking Statements

    Disclaimers and Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the “Company,” “we” or “our”) reg

  3. Slide 3: Redefining Dry Eye Treatment with a Nasal Spray

    Redefining Dry Eye Treatment with a Nasal Spray Redefining Dry Eye Treatment with a Nasal Spray

  4. Slide 4: Where Others See Challenges, We See Potential

    Where Others See Challenges, We See Potential Dry Eye Disease Remains Significant Area of Unmet Need Limitations of current treatments: • Mechanisms of action only address inflammation • Slow onset of action • Tolerability and compliance issues Despite these limitations, currently available drugs ar

  5. Slide 5: There is No Substitute for Natural Tear Film

    There is No Substitute for Natural Tear Film A healthy tear film lubricates and protects the eyes from injury and infection, washes away foreign particles, and contributes refractive power for clear vision Growth factors, such as nerve growth factor (NGF) and epidermal growth factor (EGF), found in

  6. Slide 6: Loss of Tear Film Leads to Progression of Dry Eye Disease

    Loss of Tear Film Leads to Progression of Dry Eye Disease Cycle of Dry Eye Disease Healthy Ocular Surface Loss of Tear Film Homeostasis Leads to Inflammation Tear Film Homeostasis Fundamental Characteristic of DED and Cell Damage Tear Deficiency & Instability Increased Evaporation Inflammation Irrit

  7. Slide 7: OC-01 Breaks this Cycle to Re-Establish Natural Tear Film Production

    OC-01 Breaks this Cycle to Re-Establish Natural Tear Film Production through its Novel MOA Cycle of Dry Eye Disease Healthy Ocular Surface Loss of Tear Film Homeostasis Leads to Inflammation Tear Film Homeostasis Fundamental Characteristic of DED and Cell Damage Tear Deficiency & Instability Increas

  8. Slide 8: Nasal Delivery is Critical to the Novel MOA

    Nasal Delivery is Critical to the Novel MOA Parasympathetic Nervous System controls tear film homeostasis The trigeminal nerve provides the pathway for parasympathetic stimulation of the Lacrimal Functional Unit (LFU) to promote complete natural tear film The trigeminal nerve is accessible within th

  9. Slide 9: Tear Film is Produced by the Lacrimal Functional Unit

    Tear Film is Produced by the Lacrimal Functional Unit LACRIMAL GLANDS Produce the aqueous which contains proteins, enzymes, antibodies and growth factors that are cytoprotective, anti-inflammatory, and anti-microbial. MEIBOMIAN GLANDS Produce the lipid layer which reduces evaporation and promotes te

  10. Slide 10: OC-01 is a Selective Nicotinic Agonist

    OC-01 is a Selective Nicotinic Agonist • Preservative-free nasal spray containing the selective nicotinic acetylcholine receptor agonist, varenicline. • Binds to receptors located on the trigeminal nerve readily accessible within anterior portion of the nasal cavity to open ion channels and depolari

  11. Slide 11: Mechanism of Action of OC-01

    Mechanism of Action of OC-01 11 ©2020 Oyster Point Pharma, Inc.: Confidential & ProprietaryMechanism of Action of OC-01 11 ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary

  12. Slide 12: OC-01 Attributes Deliver Against Unmet Needs in Dry Eye

    OC-01 Attributes Deliver Against Unmet Needs in Dry Eye Affects 34 MILLION ADULTS Novel mechanism of action to restore tear 1 of all ages in the U.S. alone homeostasis with natural tear production 2 and >340 million worldwide Rapid onset of action demonstrated in clinical ~16 MILLION trials to signi

  13. Slide 13: OC-01 Nasal Spray Clinical Development Program

    OC-01 Nasal Spray Clinical Development Program Top-line safety & efficacy data from 84-Day dosing in the MYSTIC Trial Neurotrophic Dry Eye Disease Keratitis PHASE 1 PHASE 2b PHASE 2 PHASE 3 PHASE 2 28-Day Long-term 84 Day 28-Day 56-Day PK Study Safety & Efficacy Safety & Efficacy Efficacy & Safety S

  14. Slide 14: OC-01 Phase 1 Study Design

    OC-01 Phase 1 Study Design Open-Label, Single-Center, Randomized, 2-way Crossover Study to Evaluate the Relative Bioavailability of Varenicline Administered as OC-01 Nasal Spray Compared to Varenicline Administered Orally 1.2 mg/ml n=11 Varenicline OC-01 Oral Tablet Nasal Spray Randomized 14 Day 1:1

  15. Slide 15: Nasal Spray Provides Low Systemic Exposure

    Nasal Spray Provides Low Systemic Exposure Systemic Exposure Mean Plasma Concentration vs. Time Highlights: • Relative bioavailability* is 13 times lower for OC-01 nasal spray as compared to oral varenicline Oral Varenicline • Maximal concentration** was 14 times Nasal Varenicline lower for OC-01 na

  16. Slide 16: OC-01 Phase 2b Study Design

    OC-01 Phase 2b Study Design Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease Placebo n=43 (Vehicle Control) Primary (sign) Endpoint: Schirmer’s Score 0.12 mg/ml n=47 Randomized at Week 4 OC-01 Sch

  17. Slide 17: Statistically Significant Improvement in Signs

    Statistically Significant Improvement in Signs Mean Change from Baseline % Subjects with ≥10mm Change in Schirmer’s Score Day 28 vs. Baseline Schirmer’s Score (mm) Day 28 Primary Endpoint P<0.001 P<0.001 P=0.001 P<0.001 P=0.001 11.4 11.1 54% 10.1 48% 45% 3.7 14% n=43 n=47 n=46 n=40 n=43 n=47 n=46 n=

  18. Slide 18: Statistically Significant Improvement in Symptoms

    Statistically Significant Improvement in Symptoms Mean Change from Baseline in Eye Mean Change from Baseline in Eye 1 2 Dryness Score (EDS) – Day 21 Dryness Score (EDS) – Day 28 Controlled Adverse Environment (CAE) Secondary Symptom Endpoint Secondary Symptom Endpoint Note: The CAE was not used for

  19. Slide 19: Statistically Significant Benefit in Corneal Staining

    Statistically Significant Benefit in Corneal Staining Mean Change in Cornea Staining Score – Day 28 Favors Favors OC-01 Placebo SD=Standard Deviation *OC-01 1.2 mg/ml was not statistically significant, but showed directional benefit favoring total, central, temporal, inferior, and nasal staining as

  20. Slide 20: Safety and Tolerability Profile

    Safety and Tolerability Profile Adverse Events Potentially Related to OC-01 Administration Events in >5% of subjects OC-01 OC-01 OC-01 Placebo (0.12 mg/mL) (0.6 mg/mL) (1.2 mg/mL) Preferred Term (n=43) (n=47) (n=48) (n=44) Sneeze after any instillation 29 (62) 38 (79) 37 (84) 0 Cough after any insti

  21. Slide 21: OC-01 Phase 2 Study Design

    OC-01 Phase 2 Study Design Single center, randomized, controlled, single-masked clinical trial to evaluate the chronic efficacy of OC-01 nasal spray on signs of dry eye disease Met primary endpoint of Mean Change in n=41 1.2 mg/ml Schirmer’s Score at Day 84 OC-01 Nasal Spray Statistically significan

  22. Slide 22: MYSTIC Subject Demographics

    MYSTIC Subject Demographics Placebo 0.6 mg/ml 1.2 mg/ml Total (n=41) (n=41) (n=41) (n=123) Mean Age at Randomization (years) 55.8 51.4 54.2 53.8 Age Range (min, max) 26, 77 28, 74 28, 74 26, 77 Male n (%) 8 (19.5) 9 (22) 6 (14.6) 23 (18.7) Sex Female n (%) 33 (80.5) 32 (78) 35 (85.4) 100 (81.3) Whit

  23. Slide 23: Study Eye - Primary Endpoint Schirmer's Score at Day 84

    Study Eye- Primary Endpoint Statistically Significant Improvement In Schirmer’s Score at Day 84 Study Eye Mean Change from Baseline in Schirmer’s Score (mm) LOCF Analysis Observed Analysis p=0.01 p=0.01 P<0.05 P<0.05 12.0 12.0 11.0 11.0 10.8 10.6 10.0 10.0 8.0 8.0 6.2 6.0 6.0 6.0 4.0 4.0 2.0 2.0 0.0

  24. Slide 24: Fellow Eye - Exploratory Schirmer's Score at Day 84

    Fellow Eye- Exploratory Statistically Significant Improvement In Schirmer’s Score at Day 84 Fellow Eye Mean Change from Baseline in Schirmer’s Score (mm) LOCF Analysis Observed Analysis p=0.01 11.0 11.0 P<0.05 P<0.05 10.0 p=0.07 8.7 8.7 9.0 9.0 7.9 7.0 7.0 4.8 4.5 5.0 5.0 3.0 3.0 1.0 1.0 Day 84 Day

  25. Slide 25: Study Eye Showed Early and Sustained Improvement

    Study Eye Showed Early and Sustained Improvement In Schirmer’s Score to Day 84 Study Eye Mean Change from Baseline in Schirmer’s Score (mm) 13.0 12.3 11.5 Highlights: 11.0 10.7 10.6 10.5 11.0 10.4 10.3 - Early Improvement in 9.0 mean change in 7.0 6.9 Schirmer’s score for 7.0 6.3 6.3 both groups in

  26. Slide 26: Magnitude of Tear Production Consistent with Prior Studies

    Magnitude of Tear Production Consistent with Prior Studies of OC-01 at Day 28 11.5 12.0 12.0 11.4 11.1 10.3 10.0 10.0 8.0 8.0 6.0 6.0 4.0 4.0 2.0 2.0 0.0 0.0 Day 28 Day 28 0.6 mg/ml 1.2 mg/ml 0.6 mg/ml 1.2 mg/ml Intent To Treat- Observed * ANCOVA, Least Squares mean n=46 n=34 n=40 n=31 26 ©2020 Oyst

  27. Slide 27: OC-01 Safety and Tolerability Profile

    OC-01 Safety and Tolerability Profile Adverse Events Potentially Related to OC-01 Administration Events in >1 subjects in any group OC-01 OC-01 Placebo (0.6 mg/mL) (1.2 mg/mL) (vehicle control) Adverse Event (Preferred Term) (n=41) (n=41) (n=41) n (%) n (%) n (%) Visual Acuity Reduced 4 (9.8) 1 (2.4

  28. Slide 28: Next: Pivotal Phase 3 Data; Topline Data On Track for Mid-2020

    Next: Pivotal Phase 3 Data; Topline Data On Track for Mid-2020 Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease Primary (sign) Endpoint: n=250 1.2 mg/ml • Schirmer’s Score at day 28 OC-

  29. Slide 29: Neurotrophic Keratitis (NK)

    Neurotrophic Keratitis (NK) NK is rare, degenerative disease resulting from a loss of corneal sensation, Disease which causes progressive damage to the cornea Causes Herpes simplex, varicella zoster (shingles), diabetes, multiple sclerosis, leprosy Corneal hypoesthesia/anesthesia, decreased tearing

  30. Slide 30: Phase 2b Neurotrophic Keratitis Trial

    Phase 2b Neurotrophic Keratitis Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray in Subjects with Neurotrophic Keratitis Primary Endpoint: n=50 Percent of subjects who achieve complete 1.2 mg/ml OC-01 resolution of corneal staining (defi

  31. Slide 31: Commercialization of OC-01

    Commercialization of OC-01 Planning 1st Launch in the US in Q4 2021 Key commercialization strategies include: Focused direct-to- Specialty sales force of Selective contracting for consumer campaigns to 150 to 200 representatives broad payer coverage targeting high volume people diagnosed with and re

  32. Slide 32: Strong Global IP Position

    Strong Global IP Position OC-01 (Varenicline) Nasal Spray OC-01, commercialized compound with patent exclusivity as a nasal spray in ocular surface disease § US license granted for varenicline tartrate by Pfizer § Three US method patents issued: expire 2035 § US formulation patent issued: expires 20

  33. Slide 33: OC-01 Nasal Spray Expected Timeline to Approval

    OC-01 Nasal Spray Expected Timeline to Approval NDA Submission - 2H 2020 New Drug Application NDA Approval - 2H 2021 Enrollment Complete- Q3 2018 Enrollment Complete - Q3 2019 Topline Data- Q4 2018 Topline Data - Q4 2019 Enrollment Complete - Q3 2019 Enrollment Complete- 1H 2020 Topline Data (Day 84

  34. Slide 34: Oyster Point Pharma

    OYSTER ©: OINT NASDAQ: OYST

Oyster Point Pharma — Corporate Update (January 2020) on 6ix